Renal and metabolic disorders depend on the renin-angiotensin system in Lyon hypertensive rats associated with diabetes

American Journal of Hypertension

Volumn 21, Issue 6, 2008, Pages 657-662

  Emonnot, Léa ^a   Cohen, Richard ^a   Lo, Ming ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; GLUCOSE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LIPID; PERINDOPRIL; RESERPINE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG INHIBITION; DYSLIPIDEMIA; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERTENSION; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY DISEASES; MALE; PERINDOPRIL; PROTEINURIA; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 44349156134     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.155     Document Type: Article

References (40)

1. Parving HH, Andersen AR, Smidt UM, Oxenboll B, Edsberg B, Christiansen JS. Diabetic nephropathy and arterial hypertension. Diabetologia 1983; 24:10-12.
2. Jarrett RJ. Hypertension in diabetic patients and differences between insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1989; 13:14-16.
3. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335:1636-1642.
4. De Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int 2004; 66:S2-S6.
5. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294:1443-1447.
6. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
7. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1993; 6:108-113.
8. Nakaya H, Sasamura H, Hayashi M, Saruta T. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12:659-666.
9. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302:210-216.
10. Bidani AK, Griffin KA, Bakris G, Picken MM. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57:1651-1661.
11. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003; 41:201-206.
12. Vincent M, Boussairi EH, Cartier R, Lo M, Sassolas A, Cerutti C, Barres C, Gustin MP, Cuisinaud G, Samani NJ, Sassard J. High blood pressure and metabolic disorders are associated in the Lyon hypertensive rat. J Hypertens 1993; 11:1179-1185.
13. Liu KL, Sassard J, Benzoni D. In the Lyon hypertensive rat, renal function alterations are angiotensin II dependent. Am J Physiol 1996; 271:R346-R351.
14. Florin M, Lo M, Liu L, Sassard J. Salt sensitivity in genetically hypertensive rats of the Lyon strain. Kidney Int 2001; 59:1865-1872.
15. Bertram D, Blanc-Brunat N, Sassard J, Lo M. Differential evolution of blood pressure and renal lesions after RAS blockade in Lyon hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2002; 283:R1041-R1045.
16. Lantelme P, Lo M, Luttenauer L, Sassard J. Pivotal role of the renin-angiotensin system in Lyon hypertensive rats. Am J Physiol 1997; 273:R1793-R1799.
17. Emonnot L, Cohen R, Lo M. Neonatal streptozotocin-induced glucose intolerance: different consequences in Lyon normotensive and hypertensive rats. J Hypertens 2007; 25:429-438.
18. Egan E, Dijoud F, Lo M, Menard J, Sassard J. Non antihypertensive doses of perindopril afford renoprotection in Lyon genetically hypertensive rats. J Hypertens 2004; 22(Suppl 2):S153-S154.
19. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
20. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc of Nephrol 2003; 14:873-880.
21. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286:F1039-F1045.
22. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.
23. Hall JE. Regulation of glomerular filtration rate and sodium excretion by angiotensin II. Fed Proc 1986; 45:1431-1437.
24. Faubert PF, Chou SY, Porush JG. Regulation of papillary plasma flow by angiotensin II. Kidney Int 1987; 32:472-478.
25. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85:541-549.
26. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, Egido J. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15:159-166.
27. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49:578-597.
28. Mento PF, Holt WF, Murphy WR, Wilkes BM. Combined rennin and converting enzyme inhibition in rats. Hypertension 1989; 13:741-748.
29. Campbell DJ, Kladis A, Duncan AM. Effects of converting inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
30. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14:1738-1747.
31. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005; 288:F1183-F1190.
32. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition. From ACEI to angiotensin II antagonists. Kidney Int 2000; 57:1803-1817.
33. Allard J, Buléon M, Cellier E, Renaud I, Pecher C, Praddaude F, Conti M, Tack I, Girolami JP. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007; 293:F1083-F1092.
34. Kakoki M, Takahashi N, Jennette JC, Smithies O. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004; 101:13302-13305.
35. Yuan G, Deng J, Wang T, Zhao C, Xu X, Wang P, Voltz JW, Edin ML, Xiao X, Chao L, Chao J, Zhang XA, Zeldin DC, Wang DW. Tissue kallikrein reverses insulin resistance and attenuates nephropathy in diabetic rats by activation of phosphatidylinositol 3-kinase/protein kinase B and adenosine 5′-monophosphate-activated protein kinase signaling pathways. Endocrinology 2007; 148:2016-2026.
36. Keane WF. The role of lipids in renal diseases: future challenges. Kidney Int 2000; 57(Suppl 75):S27-S31.
37. Attia DM, Feron O, Goldschmeding R, Radermakers LH, Vaziri ND, Boer P, Balligand JL, Koomans HA, Joles JA. Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. J Am Soc Nephrol 2004;15:949-957.
38. 1-receptor expression. Am J Physiol 1997; 272:H2701-H2707.
39. Niebauer J, Tsao PS, Lin PS, Pratt RE, Cooke JP. Cholesterol-induced upregulation of Angiotensin II and its effects on monocyte-endothelial interaction and superoxide production. Vasc Med 2001; 6:133-138.
40. Agarwal R, Curley TM. The role of statins in chronic kidney disease. Am J Med Sci 2005; 330:69-81.